Argenx's Vyvgart Priority Review and Pipeline Expansion in Focus

Argenx has received Priority Review from the FDA for its supplemental biologics license application for Vyvgart, expanding its label to reach a wider patient population with myasthenia gravis. The company is also advancing next-generation molecules and new delivery methods within its pipeline, focusing on autoimmune disease treatment and biologic drug development. The Priority Review and pipeline efforts are central to Argenx's long-term narrative, with key considerations including the potential size of Vyvgart's eventual patient base and how effectively the pipeline may support that core asset over time.